Whitehawk Therapeutics Inc
NASDAQ Global MarketTotal Valuation
Whitehawk Therapeutics Inc carries a market capitalization of 214.62M, placing it among publicly traded companies globally. Its enterprise value stands at 115.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 214.62M |
| Enterprise Value | 115.64M |
Share Statistics
Whitehawk Therapeutics Inc currently has 47.20M shares outstanding.
| Shares Outstanding | 47.20M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.64 |
| P/TBV Ratio | 2.05 |
| P/FCF Ratio | -2.21 |
| P/OCF Ratio | -2.21 |
Financial Position
Whitehawk Therapeutics Inc maintains a current ratio of 11.36, meaning it holds 11.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.36 |
| Quick Ratio | 11.13 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -64.12 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.63 |
Stock Price Statistics
Whitehawk Therapeutics Inc's stock has gained approximately 155.29412% over the past 52 weeks. The 50-day moving average sits at 4.03, while the 200-day moving average is 2.87.
| Beta (5Y) | N/A |
| 52-Week Price Change | 155.29412% |
| 50-Day Moving Average | 4.03 |
| 200-Day Moving Average | 2.87 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -122.68M, while operating income came in at -122.70M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -122.70M |
| Pretax Income | -115.81M |
| Net Income | -115.81M |
| EBITDA | -122.68M |
| EBIT | -122.70M |
| Earnings Per Share (EPS) | -1.67 |
Balance Sheet
Total book value stands at -375.44M, with working capital of 114.49M providing operational flexibility.
| Cash & Cash Equivalents | 123.04M |
| Total Debt | N/A |
| Net Debt | -34.79M |
| Equity (Book Value) | -375.44M |
| Book Value Per Share | -5.43 |
| Working Capital | 114.49M |
Cash Flow
Whitehawk Therapeutics Inc produced -107.78M in operating cash flow over the past twelve months. After subtracting -1,000.00 in capital expenditures, free cash flow totaled -107.78M - equivalent to -1.56 per share.
| Operating Cash Flow | -107.78M |
| Capital Expenditures | -1,000.00 |
| Free Cash Flow | -107.78M |
| FCF Per Share | -1.56 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.35 |
| FCF Yield | -45.15 |
Stock Splits
Whitehawk Therapeutics Inc's most recent stock split took place on August 27, 2021 with a 1:15 split ratio.
| Last Split Date | 8/27/2021 |
| Split Ratio | 1:15 |
Scores
Whitehawk Therapeutics Inc posts an Altman Z-Score of 6.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.72 |